Polysaccharide from Fuzi (FPS) Prevents Hypercholesterolemia in Rats

Xiongqing Huang¹, Juan Tang², Qin Zhou¹, Hanping Lu³, Yiling Wu⁴, Weikang Wu⁵*

Abstract

Background and aim: Polysaccharide from fuzi (FPS), a Chinese herbal medicine extract, has been demonstrated to exert lipid lowering affects. In this study we examined potential mechanisms underlying this affect, specifically alterations in expression of the LDL-receptor (LDL-R), 3-hydroxy-3-methyl glutaryl (HMG)-CoA reductase and cytochrome P450 7α-1 (CYP7α-1), using a rat model of hypercholesterolemia.

Methods and results: Male rats were fed either a normal or high cholesterol (HC) diet for two-weeks. Half of the rats on the HC diet were orally gavaged with FPS (224 mg/kg, 448 mg/kg or 896 mg/kg diet) daily. Serum lipid levels were quantified at end of the study period as were liver levels of LDL-R protein and mRNA expression of CYP7α-1 and HMG-CoA. Serum cholesterol and LDL-C concentrations were significantly elevated from control in HC rats, but not in those treated with FPS (P < 0.05). LDL-R expression was significantly decreased in the HC group compared to control (P < 0.05), but significantly increased in the FPS group (P < 0.05). HMG-CoA mRNA levels were significantly increased in the HC group compared both other groups (P < 0.05), while CYP7α-1 expression was significantly higher in the FPS group compared to both other groups (P < 0.05).

Conclusion: These findings suggest that the cholesterol lowering effect of FPS in hypercholesteremic rats is caused at least in part by increased hepatic LDL-R and CYP7α-1 expression and decreased HMG-CoA expression. Further study is needed to determine precisely where and how FPS exerts these effects. FPS offers potential as a therapeutic agent for the treatment of hypercholesterolemia.

Introduction

Hypercholesterolemia is an important risk factor for atherosclerosis and consequent cardiovascular and cerebrovascular disease. Increased circulating levels of low-density lipoprotein (LDL) underlie the development of atherosclerosis [1,2]. Statins have been shown to effectively lower LDL levels and reduce both mortality and morbidity associated with coronary heart disease by 30% [3]. However, as noted Steinberg and colleagues in a recent review [4], this still leaves a significant percentage of individuals for whom statin therapy will not prevent the occurrence of adverse events. There is an obvious need for more efficacious and alternative treatment options.

Many Chinese herbal medicines contain polysaccharides which can exert a wide range of pharmacological effects, including lipid lowering [5-10]. One such polysaccharide has been extracted from Radix Aconiti Carrumcaris Praeparata in our laboratory, designated as polysaccharide from fuzi (FPS). In previous investigations, we found have that FPS has both immunomodulatory and hypoglycemic effects [11-13]. Specifically we noted that rats treated with FPS exhibited significantly reduced cyclophosphamide-related bone marrow suppression, an increased number of peripheral white blood cells, reduced oxidative damage in the bone marrow and increased gene and protein expression of the antioxidant enzyme Cu-Zn superoxide dismutase [14,15]. Apoptosis in bone marrow cells was also inhibited (as indicated by decreased caspase-9 and -3 levels) via increased expression of the anti-apoptotic Bcl-2 gene and decreased expression of the pro-apoptotic BAX gene. Further to this, after two weeks of treatment with FPS (160 mg/kg), elevations in serum triglyceride, cholesterol and LDL levels induced by high-fat diet feeding were significantly reduced. In this
same study, the cholesterol and LDL lowering effects of FPS were similar to that of fluvastatin. The triglyceride lowering effect, however, was increased following FPS compared to fluvastatin treatment. Given its reported lipid-lowering and immunomodulatory effects, FPS may be of potential use as an anti-atherosclerotic agent.

The mechanisms underlying the lipid lowering effects of FPS have not been determined. It is essential that these mechanisms be determined to facilitate further development of this agent as a potential therapeutic. Hence the aim of the present study was to investigate the mechanisms underlying FPS-induced hypolipidemia using a rat model of diet-induced hypercholesterolemia. Specifically we examined the possibility that altered expression of three key players in hepatic lipid metabolism, the LDL-receptor (LDL-R), 3-hydroxy-3-methyl glutaryl (HMG)-CoA reductase and cytochrome P450 7a-1 (CYP7a-1), may contribute to the lipid lowering effect of FPS.

**Materials and methods**

**Animals**

Fifty male Wistar rats, aged 8-12 weeks and weighing 100 ± 10 g, provided by the Animal Centre of Sun Yat-Sen University were used. Rats were housed in a temperature controlled environment, with a fixed light/dark cycle. This study was approved by the institutional internal review board.

The rats were randomly divided into one of the five following groups: control; high cholesterol; high cholesterol + 224 mg/kg FPS; high cholesterol + 448 mg/kg FPS; high cholesterol + 869 mg/kg FPS. The dose of FPS for each treatment group was decided according to the results of our preliminary study. Hence there were 10 rats in each experimental group.

**Experimental procedure**

Hypercholesterolemia was induced by feeding the rats a diet high in cholesterol for a period of 14 days. The diet contained 2% cholesterol (Probe Biological Technology Ltd., Beijing, China), 0.5% bile salt (AOBO Star Biotechnology Ltd., Beijing, China) and a standard chow mix (0.5 ml). The sample was then centrifuged at 2500 rpm for 10 min. The supernatant (0.5 ml) was removed and mixed with ethanol (1.75 ml), 6% barium hydroxide (0.1 ml) and 10% zinc sulfate (0.05 ml). The sample was then centrifuged at 100 ± 10 g, provided by the Animal Centre of Sun Yat-Sen University were used. Rats were housed in a temperature controlled environment, with a fixed light/dark cycle. This study was approved by the institutional internal review board.

The rats were randomly divided into one of the five following groups: control; high cholesterol; high cholesterol + 224 mg/kg FPS; high cholesterol + 448 mg/kg FPS; high cholesterol + 869 mg/kg FPS. The dose of FPS for each treatment group was decided according to the results of our preliminary study. Hence there were 10 rats in each experimental group.

**Experimental procedure**

Hypercholesterolemia was induced by feeding the rats a diet high in cholesterol for a period of 14 days. The diet contained 2% cholesterol (Probe Biological Technology Ltd., Beijing, China), 0.5% bile salt (AOBO Star Biotechnology Ltd., Beijing, China) and a standard chow mix (0.5 ml). The sample was then centrifuged at 2500 rpm for 10 min. The supernatant (0.5 ml) was removed and mixed with ethanol (1.75 ml), 6% barium hydroxide (0.1 ml) and 10% zinc sulfate (0.05 ml). The sample was then centrifuged at 100 ± 10 g, provided by the Animal Centre of Sun Yat-Sen University were used. Rats were housed in a temperature controlled environment, with a fixed light/dark cycle. This study was approved by the institutional internal review board.

The rats were randomly divided into one of the five following groups: control; high cholesterol; high cholesterol + 224 mg/kg FPS; high cholesterol + 448 mg/kg FPS; high cholesterol + 869 mg/kg FPS. The dose of FPS for each treatment group was decided according to the results of our preliminary study. Hence there were 10 rats in each experimental group.

**Experimental procedure**

Hypercholesterolemia was induced by feeding the rats a diet high in cholesterol for a period of 14 days. The diet contained 2% cholesterol (Probe Biological Technology Ltd., Beijing, China), 0.5% bile salt (AOBO Star Biotechnology Ltd., Beijing, China) and a standard chow mix (0.5 ml). The sample was then centrifuged at 2500 rpm for 10 min. The supernatant (0.5 ml) was removed and mixed with ethanol (1.75 ml), 6% barium hydroxide (0.1 ml) and 10% zinc sulfate (0.05 ml). The sample was then centrifuged at
Table 1 Summary of lipid profiles in rats fed a high cholesterol diet and treated with different concentrations of FPS.

|                | Control (n = 10) | HC group (n = 10) | FPS (224 mg/kg) (n = 10) | FPS (448 mg/kg) (n = 10) | FPS (869 mg/kg) (n = 10) | P-value^a |
|----------------|-----------------|-----------------|------------------------|------------------------|------------------------|-----------|
| Cholesterol (mmol/L) | 1.33 ± 0.19     | 2.89 ± 0.48     | 2.20 ± 0.38             | 1.91 ± 0.46             | 1.93 ± 0.37             | <0.001*   |
| Triglyceride (mmol/L) | 0.79 ± 0.21     | 0.85 ± 0.33     | 0.88 ± 0.38             | 0.76 ± 0.36             | 0.87 ± 0.35             | 0.942     |
| LDL-C (mmol/L)     | 0.79 ± 0.07     | 1.97 ± 0.46     | 1.20 ± 0.15             | 1.13 ± 0.10             | 1.27 ± 0.21             | <0.001*   |
| HDL-C (mmol/L)     | 1.11 ± 0.17     | 1.22 ± 0.27     | 1.19 ± 0.24             | 1.11 ± 0.26             | 1.15 ± 0.33             | 0.830     |

Data are presented as the mean ± standard deviation.

HC = high cholesterol; FPS = Polysaccharide from Fuzi; LDL = low-density lipoprotein; HDL = high-density lipoprotein.

^aP-values are based on analysis of variance testing.

* Indicates an overall significant difference (P < 0.05).

† Indicates a statistically significant difference between the highlighted treatment group and the control group (P < 0.05).

‡ Indicates a statistically significant difference between the highlighted treatment group and the HC group (P < 0.05).

Pair-wise multiple comparisons between groups were determined using Bonferroni’s test with α = 0.007 adjustment.
are summarized in Table 2. Significant overall differences were apparent for both enzymes ($P < 0.001$). HMG-CoA reductase mRNA expression was significantly higher in the HC group compared to both the control and FPS groups ($P < 0.05$). There was no significant difference between the FPS and control group for this variable. CYP7α-1 mRNA levels were significantly higher in the FPS group compared to both the HC and control groups ($P < 0.05$).

**Discussion**

In this study we utilized a rat model of hypocholesterolemia to investigate the mechanisms underlying the lipid-lower effects of FPS, a Chinese herbal medicine extract. In the face of hypocholesterolemia, we found that treatment with FPS not only significantly reduced serum LDL and cholesterol concentrations, but also increased mRNA expression of HMG-CoA reductase and CYP7α-1 in the liver. Further to this, LDL-R expression levels were markedly decreased.

The number and activity of LDL-Rs are important factors that influence the metabolism of LDL [21,22]. This receptor internalizes LDL, thus lowering plasma LDL and cholesterol concentrations [16]. Previous studies
have shown that many hypolipidemic drugs affect LDL-R expression [23,24]. Further to this, there are a substantial number of reports indicating that various cholesterol-lowering Chinese herbal medicines also influence LDL-R expression [23]. In the present study, LDL-R immunohistochemical and Western blot analysis was performed on liver tissue obtained from rats fed a high cholesterol diet. We found that the expression of LDL-R was significantly decreased in tissue obtained from rats fed a high cholesterol diet compared to rats fed a normal diet. In contrast, rats fed the high cholesterol diet and treated with FPS exhibited no such decrease in LDL-R expression; rather the levels were significantly increased from those in control rats. Taken together, these findings lead us to suggest that one of the mechanisms through which FPS promotes cholesterol lowering is by inducing LDL-R receptor expression and density, thus enhancing the transfer, conversion and removal of LDL (and cholesterol) from the circulation.

HMG-CoA reductase is the rate-limiting enzyme of the mevalonate pathway, a key pathway of cholesterol synthesis [25]. Indeed inhibition of this enzyme in the liver by statins results in decreased cholesterol synthesis, increased LDL-R synthesis and consequent decreases in circulating levels of LDL and cholesterol [26,27]. In the present study, we found that the significantly increased hepatic HMG-CoA reductase mRNA expression levels in rats fed a high cholesterol diet were normalized by treatment with FPS. Indeed HGM-CoA reductase levels were lower (but not significantly so) in FPS treated rats compared to control rats. Hence it would appear that, similar to statins, the cholesterol lowering effect of FPS may be in part due to inhibition of hepatic HMG-CoA reductase expression. It is unclear precisely how this inhibition may be mediated (direct or upstream). Further studies are needed to determine this.

Our finding that rats fed a high cholesterol diet exhibited increased HMG-CoA reductase expression contrasts with a previous report suggesting that increased cholesterol absorption associated with a high fat diet leads to increased free cholesterol levels in hepatocytes and consequent inhibition of HMG-CoA reductase expression. It is unclear why HMG-CoA mRNA expression was increased in our study.

One of the primary sites of cholesterol metabolism is the liver, where it is converted into bile acid and subsequently excreted in feces. The rate limiting enzyme of this process is CYP7α-1. Indeed increased CYP7α-1 has been demonstrated to hasten the rate of conversion of cholesterol to bile acids in hepatocytes [27,28]. In this study we found that the hepatic mRNA expression levels of CYP7α-1 were significantly elevated in rats treated with FPS as compared to those in the control and high cholesterol groups. This finding indicates that FPS can induce expression of the CYP7α-1 gene. A further test with Western blotting also revealed that the FPS stimulated CYP7α-1 protein expression. In keeping with this finding, the levels of bile acid in fecal samples were

| mRNA levels                  | Control (n = 10) | HC group (n = 10) | FPS (n = 10) | P-value^ |
|------------------------------|------------------|-------------------|--------------|----------|
| HMG-CoA reductase            | 1.29 ± 0.36      | 4.17 ± 1.83†      | 0.73 ± 0.39‡ | <0.001*  |
| CYP7α-1                      | 0.78 ± 0.43      | 0.74 ± 0.49       | 4.08 ± 1.58‡ | <0.001*  |

Data are presented as the mean ± standard deviation.

HC = high cholesterol; FPS = Polysaccharide from Fuzi;^P-values are based on analysis of variance testing.

* Indicates an overall significant difference (P < 0.05).
† Indicates a statistically significant difference between the highlighted treatment group and the control group (P < 0.05).
‡ Indicates a statistically significant difference between the highlighted treatment group and the HC group (P < 0.05).

Pair-wise multiple comparisons between groups were determined using Bonferroni's test with α = 0.017 adjustment.
markedly elevated in rats treated with FPS, demonstrating that the increased CYP7α-1 expression resulted in heightened cholesterol metabolism. The mechanism(s) through which FPS influences CYP7α-1 expression warrants further investigation.

In this study we have explored several potential mechanisms through which FPS lowers systemic cholesterol levels using a rat model of hypercholesterolemia. We report for the first time that alterations in the hepatic LDL-R, CYP7α-1 and HMG-CoA expression at least in part appear to underlie this effect. Our findings suggest that FPS has the capacity to influence cholesterol handling at multiple points in the metabolic process. Further studies are needed to determine precisely where and how in the various pathways monokind polypeptide influence expression of the LDL receptor, CYP7α-1 and HMG-CoA reductase. The efficacy of this potential lipid lowering agent also warrants investigation in humans.

Acknowledgements
This work was supported by the National Nature Science foundation of China (No. 30070930).

Author details
1Department of Anesthesiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, PR China. 2Guangzhou Critical Care Medicine Department, Guangzhou Women and Children’s Medical Center, Guangzhou 510120, PR China. 3Department of Nuclear Medicine, Zhongshan Medical College, Sun Yat-sen University, Guangzhou 510089, PR China. 4Hebei Yiling Pharmaceutical Research Institute, Shijiazhuang 050035, PR China. 5Institute of Integrated Traditional Chinese and Western Medicine, Zhongshan Medical College, Sun Yat-sen University, Guangzhou 510089, PR China.

Authors’ contributions
We declare that all the listed authors have participated actively in the study and all meet the requirements of the authorship.

WW designed the study and wrote the protocol. XH managed the literature searches and analyses. XH and WW wrote the first draft of the manuscript. All authors undertook the data collection, and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 17 November 2009
Accepted: 28 January 2010 Published: 28 January 2010

References
1. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, Shimamura K, Kimura J, Michishita J, Suzuki T, Nagai R. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. J Atheroscler Thromb Vasc Biol 2000, 2010(1):2243-2247.
2. Steinberg D. Lipoprotein and the pathogenesis of atherosclerosis. J Clin Lipid Cardiacvas; dis 1987, 763(5):508-513.
3. Baggent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Soujnia T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
4. Steinberg D, Glass CK, Witztum JL. Evidence mandating earlier and more aggressive treatment of hypercholesterolemia. Circulation 2008, 118:672-677.
5. Inoue N, Yamano N, Sakata K, Nagao K, Hama Y, Yanagita T. The Sulfated Polysaccharide Porphyran Reduces Apoliprotein B100 Secretion and Lipid Synthesis in HepG2 Cells. Biosci Biotechnol Biochem 2009, 73(2):447-449.
6. Singh V, Kaul S, Chander R, Kapoor NK. Stimulation of LDL receptor activity in liver membranes of guggulsterone treated rats. J Pharmacol Res 1990, 22:57-50.
7. Ishii K, Takakuwa T, Takeo T. Anti-diabetes mellitus effect of watersoluble tea polysaccharide. Proceedings of international symposium on Tea Science Shizuka, Japan: The Organizing committee of ISTS 1991, 240-241.
8. Kanauchi O, Deuchi K, Imasato Y, Shizukuishi M, Kobayashi E. Mechanism for the inhibition of fat digestion by chitosan and for the synergistic effect of ascorbic acid. J Biosci Biotechnol Biochem 1996, 59(5):786-790.
9. Maezaki Y, Tsuji K, Nakagawa Y, Kawai Y, Akimoto M, Tsugita T, Wataru T, Atsushi T, Hiroyoshi H, Tomotari M. Hypcholesterolemic effect of chitosan in adult males. J Biosci Biotechnol Biochem 1993, 57(9):1439-1444.
10. Omrod DJ, Holmes CC, Miller TE. Dietary chitosan inhibits hypercholesterolaemia and atherogenesis in the apolipoprotein E-deficient mouse model of atherosclerosis. J Atherosclerosis 1998, 138(2):329-334.
11. Zhao C, Li M, Luo Y, Wu W. Isolation and structural characterization of an immunostimulating polysaccharide from fuzi, Aconitum carmichaelia. Carb Polysaccharides 2006, 341:485-491.
12. Nazarova IV, Shechenko NM. Immunomodulatory properties of polysaccharaides from red algae in influence on the complement system. J Biol Biochemistry Russia 1998, 24(1):47.
13. Okai Y, Ishizaka S, Higashi Okai K, Yamashita U. Detection of immunomodulating activities in an extract of Japanese edible seaweed, Laminaria japonica (Maknbush). J Sea Food Agr 1996, 72(4):65.
14. Lin S, Liu K, Wu W, Chen C, Wang Z, Zhang X. Study on Pretreatment of FPS-1 in Rats with Hepatic Ischemia-Reperfusion Injury. Am J Chin Med 2009, 37(2):323-37.
15. Li L, Ng TB, Song M, Yuan F, Liu ZK, Wang CL, Jiang Y, Fu M, Liu F. A polysaccharide-peptide complex from abalone mushroom (Pleurous abalonus) fruiting bodies increases activities and gene expression of antioxidant enzymes and reduces lipid peroxidation in senesence-accelerated mice. Appl Microbiol Biotechnol 2007, 75:863-869.
16. Meddings JB, Spady DK, Dietzsch JM. Kinetic characteristics and mechanisms of regulation of receptor-dependent and receptor-independent LDL transport in the liver of different animal species and humans. Am J Heart 1997, 113:475-481.
17. Yokogoshi H, Mochizuki H, Nanami K, Hida Y, Miyachi F, Oda H. Dietary Taurine Enhances Cholesterol Degradation and Reduces Serum and Liver Cholesterol Concentrations in Rats Fed a High-Cholesterol Diet. J Nutr 1999, 129:1705-1712.
18. Becker K, Pan D, Whiteley CB. Real-time quantitative polymerase chain reaction to assess gene transfer. Hum Gene Ther 1999, 10:2559-2566.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-Delta Delta C(T) Method. Methods 2001, 25(4):402-8.
20. Reint J, Reiser J, Stark GR. Transfer of proteins from gels to dialzobenzoloxymethyl-paper and detection with antiseria: a method for studying antibody specificity and antigen structure. Proc Natl Acad Sci USA 1979, 76(7):3116-3120.
21. Liu HD, Withcombe SK, Walker G, Rong JX, Walzem RL, Wong JS, Hamilton RL, Fisher EA, Young SG. Eliminating atherosclerosis in mice by switching off hepatic lipoprotein. Circulation 2003, 107:1315-1322.
22. Pataky M, Lofgren IE, Freake HC, Koo SI, Fernandez ML. The lowering of plasma lipids following a weight reduction program is related to accelerated ubiquitination and degradation of HMG CoA reductase. J Nutr 2005, 135:735-739.
23. Fukushima M, Nakano M, Moriy Y, Ohashi T, Fujiwara Y, Sonoyama K. Hepatic LDL receptor mRNA in rats is increased by dietary mushroom (Agaricus bisporus) fiber and sugar beet fiber. J Nutr 2000, 130:2151-2156.
24. Murakami S, Nitanai I, Uchida S, Kondo-Ohta Y, Asami Y, Kondo K, Sato M, Kawashima A, Haru H, Tomisawa K, Miw H, Xiang C. Up-regulation of low density lipoprotein receptor by a novel isobenzofuranone derivative, MD-700. Atherosclerosis 1999, 146:281-290.
25. Bose-Boyd RA. Feedback regulation of cholesterol synthesis: sterol- accelerated ubiquitination and degradation of HMG CoA reductase. Cell Res 2008, 18:609-621.
26. Brookes ZL, McGown CC, Reilly CS: Statins for all: the new premed?. Br J Anaesth 2009, 103:99-107.
27. Garcia-Mediavilla V, Villares C, Culebras JM, Bayon JE, Gonzalez-Gallego J: Effects of dietary beta-cyclodextrin in hypercholesterolaemic rats. Pharmacol Toxicol 2003, 92:94-99.
28. Férézou J, Riottot M, Sérougne C, Cohen-Solal C, Catala I, Alquier C, Parquet M, Juste C, Lafont H, Mathé D, Corring T, Lutton C: Hypcholesterolemic action of beta-cyclodextrin and its effects on cholesterol metabolism in pigs fed a cholesterol-enriched diet. J Lipid Res 1997, 38:86-100.

doi:10.1186/1476-511X-9-9
Cite this article as: Huang et al: Polysaccharide from Fuzi (FPS) Prevents Hypercholesterolemia in Rats. Lipids in Health and Disease 2010 9:9.